Glenda Gray to AIDS Vaccines
This is a "connection" page, showing publications Glenda Gray has written about AIDS Vaccines.
Connection Strength
6,506
-
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults. N Engl J Med. 2021 03 25; 384(12):1089-1100.
Score: 0,642
-
Review of preventative HIV vaccine clinical trials in South Africa. Arch Virol. 2020 Nov; 165(11):2439-2452.
Score: 0,615
-
HIV research in South Africa: Advancing life. S Afr Med J. 2019 Dec 05; 109(11b):36-40.
Score: 0,586
-
Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Sci Transl Med. 2019 09 18; 11(510).
Score: 0,578
-
Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. Clin Vaccine Immunol. 2016 06; 23(6):496-506.
Score: 0,460
-
Approaches to preventative and therapeutic HIV vaccines. Curr Opin Virol. 2016 04; 17:104-109.
Score: 0,453
-
Reevaluating HIV vaccine clinical trials policy for infants. J Infect Dis. 2015 Feb 15; 211(4):501-3.
Score: 0,407
-
Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses. PLoS One. 2014; 9(8):e103446.
Score: 0,405
-
Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infect Dis. 2014 May; 14(5):388-96.
Score: 0,393
-
Does participation in an HIV vaccine efficacy trial affect risk behaviour in South Africa? Vaccine. 2013 Apr 12; 31(16):2089-96.
Score: 0,365
-
Willingness to participate in biomedical HIV prevention studies after the HVTN 503/Phambili trial: a survey conducted among adolescents in Soweto, South Africa. J Acquir Immune Defic Syndr. 2011 Oct 01; 58(2):211-8.
Score: 0,333
-
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis. 2011 Jul; 11(7):507-15.
Score: 0,324
-
Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS. 2010 Sep; 5(5):357-61.
Score: 0,309
-
Benign ethnic neutropenia in a South African population, and its association with HIV acquisition and adverse event reporting in an HIV vaccine clinical trial. PLoS One. 2021; 16(1):e0241708.
Score: 0,159
-
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. PLoS Med. 2020 02; 17(2):e1003038.
Score: 0,149
-
Projected economic evaluation of the national implementation of a hypothetical HIV vaccination program among adolescents in South Africa, 2012. BMC Public Health. 2016 Apr 14; 16:330.
Score: 0,114
-
The Case for Adolescent HIV Vaccination in South Africa: A Cost-Effectiveness Analysis. Medicine (Baltimore). 2016 Jan; 95(4):e2528.
Score: 0,112
-
Uptake of genital mucosal sampling in HVTN 097, a phase 1b HIV vaccine trial in South Africa. PLoS One. 2014; 9(11):e112303.
Score: 0,103